AUMED a.s. founded a new company AUMED Immunology a.s.. AUMED, a.s. is the sole shareholder of the newly formed company. The company AUMED Immunology a.s. was founded with the aim of registering and marketing a new medicinal product containing transfer factor as an active medicinal substance in the form of an oral lyophilized tablet. The new medicinal product will be based on the results of own research activities in the field of transfer factors (more detailed information here). The registration plan for a newly developed medicinal product belongs to the long-term business concept and strategy of AUMED, a.s..
AUMED representatives participated in the 45th ICMM World Congress on Military Medicine held in Brisbane, Australia. At the congress, AUMED…
AUMED representatives participated in the prestigious conference Viruses of Microbes 2024, which was held in the city of Cairns, Australia….
Now you can order Phage Glow Bioactive acne gel in a new package. This revolutionary beauty product based on phage…
Research projects of Aumed, a.s. are financed by the European Structural Funds and with financial support from the state budget through the Ministry of Industry and Trade. A complete list of all ongoing and completed projects with this support can be found here.
Ministry of Industry and Trade
Program TRIO
European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness
Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s
